Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Federal Trade Commission
US Army
QuintilesIMS
Harvard Business School
UBS

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,673,838

« Back to Dashboard

Which drugs does patent 6,673,838 protect, and when does it expire?

Patent 6,673,838 protects PRISTIQ and is included in one NDA.

This patent has forty-six patent family members in thirty-one countries.

Summary for Patent: 6,673,838
Title: Succinate salt of O-desmethyl-venlafaxine
Abstract:A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
Inventor(s): Hadfield; Anthony F. (Nanuet, NY), Shah; Syed M. (East Hanover, NJ), Winkley; Michael W. (Campbell Hall, NY), Sutherland; Karen W. (New City, NY), Provost; James A. (Waltham Chase, GB), Park; Aeri (West Lafayette, IN), Shipplett; Rex A. (Wolcott, IN), Russell; Brenton W. (West Lafayette, IN), Weber; Beat T. (Zofingen, CH)
Assignee: Wyeth (Madison, NJ)
Application Number:10/073,743
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,673,838
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,673,838
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Formulation; Use;

Drugs Protected by US Patent 6,673,838

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No ➤ Sign Up ➤ Sign Up Y MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No ➤ Sign Up ➤ Sign Up Y FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION ➤ Sign Up
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION ➤ Sign Up
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION ➤ Sign Up
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 6,673,838

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 032671 ➤ Sign Up
Argentina 082076 ➤ Sign Up
Austria 369330 ➤ Sign Up
Australia 2002250058 ➤ Sign Up
Brazil 0207157 ➤ Sign Up
Canada 2436668 ➤ Sign Up
Canada 2666611 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKinsey
Express Scripts
Chinese Patent Office
Cantor Fitzgerald
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.